EUVIMEDEUVIMED entdecken
Vergleichsstudie

Efficacy and Safety of Prophylactic Anticoagulation Versus Therapeutic Anticoagulation After Iliac Vein Stenting in Patients with a Nonthrombotic Iliac Vein Lesion

Yi-Hui Qiu, Yin-He Zhang, Zi-Chang Wu, Jia-Cheng Zhang, Zhe Yang, Guan-Xia Zhu, Shou-Liang Miao, Fan-Feng Chen, Bi-Cheng Chen

Annals of Vascular Surgery · 2026-07 · 128 · 123-131

DOI: 10.1016/j.avsg.2026.02.040 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Annals of Vascular Surgery, 2026-07. Verfasst von Yi-Hui Qiu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Vascular Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China. Hauptthemen laut MEDLINE: Iliac Vein, Stents, Anticoagulants, Endovascular Procedures. Die Arbeit nennt 43 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The long-term patency of stents is notably high in patients undergoing stenting for nonthrombotic iliac vein lesions (NIVLs). Consequently, the postoperative antithrombotic strategy of employing therapeutic anticoagulation (TA) in these patients has been called into question. This study aims to compare the clinical outcomes of prophylactic versus TA at our center. METHODS: In this single-institution retrospective study, a total of 155 patients with NIVLs who were prescribed either prophylactic or therapeutic doses of anticoagulation for a duration of 3 months following stent placement were enrolled. The outcomes assessed during follow-up included primary patency, bleeding events, mortality, the revised venous clinical severity score (r-VCSS) and symptom recurrence. RESULTS: From October 2012 to April 2024, 82 patients received prophylactic anticoagulation (PA) and 73 TA, with a median follow-up period of 42 months. There was no significant difference between the PA group and the TA group in rates of primary patency (98.8% vs. 95.9%, P = 0.292, hazard ratio [HR] 0.317, 95% confidence interval [CI] 0.045 to 2.252), mortality (4.9% vs. 6.8%, P = 0.957, HR 1.035, 95% CI 0.277 to 3.866), as well as symptom recurrence (7.3% vs. 11.0%, P = 0.456, HR 0.670, 95% CI 0.235 to 1.914). In addition, the major bleeding events (0.0% vs. 1.4%, P = 0.471), the clinically relevant nonmajor bleeding events (3.7% vs. 8.2%, P = 0.385), total bleeding events (3.7% vs. 9.6%, P = 0.241), and the changes in the r-VCSS from baseline to 6 months postoperatively (5.00 [3.00, 6.00] vs. 5.00 [3.00, 6.00], P = 0.643) were also not significantly different in the 2 groups. CONCLUSION: In patients with NIVLs, PA after iliac vein stenting exhibited similar clinical outcomes when compared with TA. This finding suggests that PA may be sufficient. Furthermore, the nonanticoagulation regimens merit further investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Iliac VeinStentsAnticoagulantsEndovascular ProceduresHumansRetrospective StudiesFemaleMaleTreatment OutcomeTime FactorsVascular PatencyMiddle AgedRisk FactorsAgedRecurrenceHemorrhageRisk Assessment

Substanzen

Anticoagulants

Autor:innen und Institutionen

  • Department of Vascular Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
  • Molecular Pharmacology Research Center, School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, China.
  • The Second Affiliated Hospital & The Second Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, China.
  • Department of Radiology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
  • Key Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China. Electronic address: bichengchen9@126.com.

Zitieren

APA

Qiu, Y. H., Zhang, Y. H., Wu, Z. C., Zhang, J. C., Yang, Z., Zhu, G. X., Miao, S. L., Chen, F. F., & Chen, B. C. (2026). Efficacy and Safety of Prophylactic Anticoagulation Versus Therapeutic Anticoagulation After Iliac Vein Stenting in Patients with a Nonthrombotic Iliac Vein Lesion. Annals of Vascular Surgery, 128, 123-131. https://doi.org/10.1016/j.avsg.2026.02.040

Vancouver

Qiu YH, Zhang YH, Wu ZC, Zhang JC, Yang Z, Zhu GX, et al. Efficacy and Safety of Prophylactic Anticoagulation Versus Therapeutic Anticoagulation After Iliac Vein Stenting in Patients with a Nonthrombotic Iliac Vein Lesion. Annals of Vascular Surgery. 2026;128:123-131. doi:10.1016/j.avsg.2026.02.040

BibTeX
@article{Qiu2026,
  author = {Qiu, Yi-Hui and Zhang, Yin-He and Wu, Zi-Chang and Zhang, Jia-Cheng and Yang, Zhe and Zhu, Guan-Xia and Miao, Shou-Liang and Chen, Fan-Feng and Chen, Bi-Cheng},
  title = {Efficacy and Safety of Prophylactic Anticoagulation Versus Therapeutic Anticoagulation After Iliac Vein Stenting in Patients with a Nonthrombotic Iliac Vein Lesion},
  journal = {Annals of Vascular Surgery},
  year = {2026},
  volume = {128},
  pages = {123--131},
  doi = {10.1016/j.avsg.2026.02.040}
}
Kostenlos starten →